1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

PharmaPoint: Colorectal Cancer - 5EU Drug Forecast and Market Analysis to 2023

  • November 2014
  • 210 pages
  • GlobalData
Report ID: 2584210

Summary

Table of Contents

Search Inside

PharmaPoint: Colorectal Cancer - 5EU Drug Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Country Evaluation report, “PharmaPoint: Colorectal Cancer - 5EU Drug Forecast and Market Analysis to 2023”. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.

Growth of the French market is expected to be driven by increasing disease incident cases as the population ages, label extension of Stivarga as an adjuvant treatment for resected liver metastases patients, and the launch of expensive new therapies such as MGN-1703, a maintenance therapy for first-line patients responding to chemotherapy with or without biological agents. Germany has shifted towards a strict reference pricing system and has begun implementing price cuts, indicating that pharmaceutical companies can no longer count on the free pricing schemes previously in place in the German market. GlobalData believes that the government is likely to make similar moves in the future. As in the 5EU in general, cost effectiveness is a major priority for the Italian government and will be a major limitation on the pricing and uptake of new drugs during the forecast period. The Spanish government has been forced to institute severe cost-control measures due to economic policies stemming from the 2008 financial crisis. Growth in the UK is expected to be restricted by the NHS reimbursement watchdog, NICE. At present, no branded treatments have been given approval from NICE in the UK.

Scope

- Overview of CRC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU CRC market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for CRC
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in 5EU.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Epiomic Epidemiology Series: BRCA 1 & 2 Mutation in Cancer Forecast in 18 Major Markets 2017-2027

  • $ 6859
  • Industry report
  • June 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on BRCA1 and BRCA2 mutation in Cancer in 18 Major Markets It has long been established that BRCA1 and BRCA2 (BReast CAncer susceptibility ...

Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

“Blood Tests replace Surgical Biopsies. Single screening test for all cancers announced .....” The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics ...

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and ...


Download Unlimited Documents from Trusted Public Sources

Global Mortality Industry

  • June 2017
    4 pages
  • Mortality  

    Cancer  

    Dementia  

  • United States  

    World  

View report >

Therapy Market in the US and the UK

  • June 2017
    11 pages
  • Therapy  

  • United States  

    United Kingdom  

    Europe  

View report >

Cancer Statistics in Singapore

  • June 2017
    43 pages
  • Cancer  

  • Singapore  

    China  

    India  

View report >

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.